T. Rowe Price Associates’s Adicet Bio ACET Stock Holding History

T. Rowe Price Associates’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-959	Closed	-$37K	–	2921
2024 Q1	$37K	Buy	+959	New	+$39.7K	﹤0.01%	2898

Other funds holding ACET

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

T. Rowe Price Associates's ACET Position: Q2 2024 in Review

T. Rowe Price Associates sold out of Adicet Bio (ACET) in Q2 2024, closing a stake of 959 shares — an estimated $37K sold.

T. Rowe Price Associates first reported a position in ACET in Q1 2024 and held it in 1 quarter. The position peaked at $37K in Q1 2024. 86 funds tracked by Wall St. Rank hold ACET as of Q2 2024.

T. Rowe Price Associates reported no remaining Adicet Bio position as of Q2 2024 after selling out during the quarter.
T. Rowe Price Associates sold 959 Adicet Bio shares in Q2 2024, an estimated $37K.
T. Rowe Price Associates first reported a position in Adicet Bio in Q1 2024 and held it in 1 quarter.
T. Rowe Price Associates's Adicet Bio position peaked at $37K in Q1 2024.
86 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2024.

Based on T. Rowe Price Associates's 13F filing for Q2 2024, filed 14 Aug 2024.